Table 1.
Demographic characteristics according to blood type.
| A (n = 461, 47.5%) | B (n = 145, 15.0%) | 0 (n = 279, 28.8%) | AB (n = 84, 8.7%) | TOTAL (n = 969, 100%) | |
|---|---|---|---|---|---|
| Age- median (min- max) | 52 (18 - 92) | 49 (20 - 93) | 55 (18 - 95) | 53 (22 - 93) | 53 (18 - 95) |
| < 65 age | N = 316, 68.5% | N = 101, 69.7% | N = 184, 65.9% | N = 64, 76.2% | N = 665, 68.6% |
| ≥ 65 age | N = 145, 31.5% | N = 44, 30.3% | N = 95, 34.1% | N = 20, 23.8% | N = 304, 31.4% |
| Gender | |||||
| Female | N = 240, 52.1% | N = 63, 43.4% | N = 132, 47.3% | N = 41, 48.8% | N = 476, 49.1% |
| Male | N = 221, 47.9% | N = 82, 56.6% | N = 147, 52.7% | N = 43, 51.2% | N = 493, 50.9% |
| Comorbidity | |||||
| Diabetes | N = 101, 21.9% | N = 25, 17.2% | N = 64, 22.9% | N =19, 22.6% | N = 209, 21.6% |
| Hypertension | N = 195, 42.3% | N = 51, 35.2% | N = 121, 43.5% | N = 44, 52.4% | N = 411, 42.5% |
| Chronic renal failure | N = 26, 5.6% | N = 7, 4.8% | N = 16, 5.7% | N = 5, 6% | N = 54, 5.6% |
| Ischemic heart disease | N = 90, 19.5% | N = 18, 12.4% | N = 61, 21.9% | N = 8, 9.5% | N = 177, 18.3% |
| KOAH | N = 36, 7.8% | N = 11, 7.6% | N = 33, 11.8% | N = 5, 6% | N = 85, 8.8% |
| Lab Findings at Presentation | |||||
| White-cell count (x103 cells/µL) | 7 (1 - 47.7) 8.1 ± 4.7 |
7.7 (1 - 32.6) 8.5 ± 4.6 |
7 (0.4 - 121.1) 8.9 ± 10.3 |
6.8 (1.1 - 22.6) 7.8 ± 3.9 |
7.1 (0.4 - 121.1) 8.4 ± 6.8 |
| Neutrophil count (x103 cells/µL) | 4.2 (0.3 - 41.9) 5.5 ± 4.4 |
4.7 (0.6 - 31.1) 6.2 ± 4.6 |
4.3 (0.1 - 32.5) 5.8 ± 4.8 |
4.2 (0.2 - 19.3) 5.1 ± 3.6 |
4.3 (0.1 - 41.9) 5.7 ± 4.5 |
| Lymphocyte count (x103 cells/µL) | 1.7 (0.18 - 196) 2.3 ± 9 .2 |
1.6 (0.06 - 3.7) 1.7 ± 0.82 |
1.6 (0.22 - 5.5) 1.7 ± 0.87 |
1.8 (0.24 -4.4) 1.9 ± 0.99 |
1.7 (0.06 - 196) 2 ± 6.4 |
| Platelet count (x103 cells/µL) | 228 (11 - 1333) 240 ± 97.3 |
238 (56 - 498) 242 ± 80.6 |
215 (28 - 779) 232.8 ± 91.8 |
217 (11.3 - 597) 238.5 ± 86 |
225 (11 - 1333) 238 ± 92.4 |
| CRP (mg/L) | 16.5 (3 - 403) 42.4 ± 58.1 |
18.8 (3 - 319) 50.2 ± 62 |
16.4 (3 - 439) 45.5 ± 65 |
12.1 (3 - 341) 44.1 ± 68.6 |
16.5 (3 - 439) 44.7 ± 61.7 |
| D- dimer (µg/mL) | 0.6 (0.2 - 263) 2.7 ± 14.3 |
0.7 (0.2 - 24) 2.2 ± 4 |
0.6 (0.2 - 74) 1.9 ± 5.6 |
0.6 (0.2 - 30) 2.2 ± 5.1 |
0.6 (0.2 - 263) 2.3 ± 10.6 |
| Ferritin (ng/mL) | 129.3 (4.6 - 16 830) 347.1 ± 1182.2 |
126.2 (5.6 – 2,000) 278.5 ± 426.6 |
132 (8 - 3141) 297.1 ± 478 |
116.3 (9.7 -1744) 266.1 ± 424 |
128.3 (4.6 – 16,830) 316 ± 885.2 |
| Fibrinojen (mg/dL) | 438.5 (44 - 900) 460.7 ± 169.2 |
447 (140 - 900) 482.4 ± 191.4 |
437 (48 - 900) 462.7 ± 172.3 |
411 (228 - 900) 460.1 ± 187.9 |
438 (44 - 900) 464.5 ± 175 |
| Troponin (pg/mL) | 4.7 (3 - 2411) 53.2 ± 217.1 |
6 (3 – 5,936) 92.7 ± 579.2 |
6.2 (3 - 983) 34.7 ± 93.2 |
4.1 (3 - 996) 35.3 ± 120.5 |
5 (3 - 5936) 52.3 ± 277.6 |
| CK-MB (U/L) | 2 (0.4 - 345) 7 ± 33.9 |
1.8 (0.6 - 25.1) 3 ± 4.5 |
2.3 (0.3 - 204) 7 ± 26.2 |
1.7 (0.8 - 22.3) 3.3 ± 5.2 |
2 (0.3 - 345) 6.2 ± 27.6 |
| Anemia | |||||
| Yes | N = 209, 46% | N = 62, 43.4% | N = 136, 49.1% | N = 36, 42.9% | N = 443, 46.2% |
| No | N = 245, 54% | N = 81, 56.6% | N = 141, 50.9% | N = 48, 57.1% | N = 515, 53.8% |
| Thorax CT involvement | |||||
| Yes | N = 229, 95.8% | N = 76, 96.2% | N = 138, 97.9% | N = 47, 95.9% | N = 490, 96.5% |
| No | N = 10, 4.2% | N = 3, 3.8% | N = 3, 2.1% | N = 2, 4.1% | N = 18, 3,5% |
| Treatments administered | |||||
| Hydroxychloroquine | N = 456, 99.3% | N = 145, 100% | N = 276, 99.6% | N = 82, 97.6% | N = 965, 99.4% |
| Oseltamavir | N = 235, 51.9% | N = 64, 44.1% | N = 136, 50% | N = 43, 51.2% | N = 478, 50.1% |
| Azithromycin | N = 302, 65.8% | N = 90, 62.1% | N = 180, 65.7% | N = 56, 66.7% | N = 628, 65.3% |
| DMAH | N = 271, 58.8% | N = 97, 66.9% | N = 169, 60.8% | N = 52, 61.9% | N = 589, 60.8% |
| Favipravir | N = 56, 12.4% | N = 29, 20% | N = 39, 14.2% | N = 10, 12% | N = 134, 14% |
| Tosilizumab | N = 2, 0.4% | N = 2, 1.4% | N = 2, 0.7% | N = 2, 2.4% | N = 8, 0.8% |
| Mortality | N = 38, 86.4% | N = 14, 93.3% | N = 17, 70.8% | N = 4, 80% | N = 73, 83% |